WO2018230459A1 - Composition à usage oral et promoteur de croissance de bactéries buccales communes - Google Patents

Composition à usage oral et promoteur de croissance de bactéries buccales communes Download PDF

Info

Publication number
WO2018230459A1
WO2018230459A1 PCT/JP2018/022002 JP2018022002W WO2018230459A1 WO 2018230459 A1 WO2018230459 A1 WO 2018230459A1 JP 2018022002 W JP2018022002 W JP 2018022002W WO 2018230459 A1 WO2018230459 A1 WO 2018230459A1
Authority
WO
WIPO (PCT)
Prior art keywords
oral
formula
component
oral cavity
bacteria
Prior art date
Application number
PCT/JP2018/022002
Other languages
English (en)
Japanese (ja)
Inventor
丸山　真達
小林　利彰
大 由木
隆太郎 城
絢矢 川井
謙二 大内
聡 稲冨
Original Assignee
ライオン株式会社
ホクト株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社, ホクト株式会社 filed Critical ライオン株式会社
Priority to CN201880039297.9A priority Critical patent/CN110740721B/zh
Priority to KR1020197038567A priority patent/KR102614880B1/ko
Publication of WO2018230459A1 publication Critical patent/WO2018230459A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
    • A23J7/00—Phosphatide compositions for foodstuffs, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
    • A23F3/00—Tea; Tea substitutes; Preparations thereof
    • A23F3/06—Treating tea before extraction; Preparations produced thereby
    • A23F3/14—Tea preparations, e.g. using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils

Definitions

  • the present invention relates to a growth promoter for resident bacteria in the oral cavity and an oral composition containing the same.
  • the current oral care is aimed at preventing oral diseases such as caries and periodontal disease. For this reason, technologies such as sterilization of pathogenic bacteria and pathogenic bacteria biofilms causing dental caries and periodontal disease, strengthening of tooth quality and gums, and anti-inflammation have been developed and commercialized.
  • resident bacteria symbiotic to humans are greatly involved in maintaining and promoting human health. It has been reported that intestinal resident bacteria are important for human intestinal regulation, and that they are involved in improving immunity and obesity. Conventionally, some lactic acid bacteria have been utilized as products represented by yogurt as probiotics.
  • oral bacteria As for oral bacteria, it is known that resident bacteria such as Streptococcus and Rothia have antibacterial activity against pathogenic bacteria. Oral diseases are not infections caused by pathogenic bacteria alone, but multiple bacterial infections involving resident bacteria represented by these, and it is considered that resident bacteria other than pathogenic bacteria are involved in the onset and progression of oral diseases. It is done. Furthermore, the relationship between oral bacteria and enteritis and Alzheimer's disease has been reported, and it has begun to be shown that oral bacteria may be involved not only in the oral cavity but also in human general health. Therefore, it is important for oral care not only to eliminate pathogenic bacteria in the oral cavity, but also to maintain resident bacteria and keep them in a particularly healthy state.
  • sterilization which is the mainstream of current bacterial control, has a problem of sterilizing and removing not only pathogenic bacteria but also other resident bacteria.
  • antibodies have been studied as a technique for selectively suppressing only pathogenic bacteria, but sufficient effects have not been obtained.
  • Patent Document 1 Japanese Patent No. 2794072 proposes that phosphatidylglycerol and / or lysophosphatidylglycerol has a good antibacterial action and is effective as an antibacterial agent for cosmetics and the like.
  • Patent Document 2 Japanese Patent Laid-Open No.
  • a surfactant lysophosphatidylcholine is effective in preventing a decrease in the bactericidal activity of a phenolic fungicide in an oral composition.
  • No. 88333 proposes that lysophospholipids such as lysophosphatidic acid have alveolar bone absorption inhibitory action and inflammatory cytokine secretion inhibitory action and are effective in preventing or improving oropharyngeal disease and periodontal disease. is doing.
  • Patent Document 4 Japanese Patent Laid-Open No. 7-67552 discloses that acidic phospholipids or lyso forms thereof are excellent in the bitterness reducing effect of bitter substances such as cosmetics as an active ingredient of a bitterness reducing agent.
  • the present invention has been made in view of the above circumstances, and an object thereof is to provide a growth promoting agent for oral resident bacteria, which is excellent in the growth promoting effect for oral resident bacteria, and an oral composition containing the same. To do.
  • the present inventors have found that a compound represented by Structural Formula (1) or a salt thereof described later, a compound represented by Structural Formula (2) or a salt thereof, and When used in combination at a specific ratio, it has an excellent effect of promoting the growth of oral resident bacteria, and it is found that the composition for oral cavity containing this combination system has an excellent effect of promoting the growth of oral resident bacteria.
  • the present invention has been made.
  • the mass ratio of (A) / (B) is excellent in the growth promoting effect of oral resident bacteria within a specific range, especially resident other than pathogenic bacteria
  • Streptococcus Streptococcus belonging to the Mittis group, it has an action effect that has not been known so far, but promotes its growth, not an antibacterial action.
  • the combination of the components (A) and (B) according to the present invention can be used for a new use as a growth promoter for resident bacteria in the oral cavity, and preferably used as an active ingredient for an oral composition.
  • some lecithins and lysolecithins have antibacterial activity, but for microorganisms such as bacteria, the action of antibacterial agents is complicated and acts on certain microorganisms. However, it cannot be generally said that it acts on other microorganisms as well.
  • the component (A) alone exhibits an antibacterial effect on pathogenic bacteria (periodontopathic bacteria Porphyromonas gingivalis), but otherwise The effect of promoting the growth of the resident bacterium (Streptococcus spp. Of the Mittis group) is not observed (Comparative Example 1), and the component B (B) alone does not promote the growth of the resident bacteria. (Comparative example 2).
  • the components (A) and (B) are combined at a specific ratio, surprisingly, there is an excellent effect of promoting the growth of the above-mentioned resident bacteria, It can also give antibacterial effects against pathogenic bacteria.
  • Such an effect of the present invention is inferior when the amount ratio of both is inappropriate even when the components (A) and (B) are combined (Comparative Examples 3 and 4), and (A) / ( B) Specific and exceptionally prominent that the ratio can only be obtained within a certain range.
  • the pathogenic bacteria are Porphyromonas gingivalis, a causative agent of periodontal disease, and Streptococcus mutans, a causative agent of caries.
  • Streptococcus mutans There are only several types of bacteria represented by (Streptococcus mutans). Most of the rest are Streptococcus gordonii, Streptococcus mitis, Streptococcus oralis, and M. streptococcus oralis, which are representative of the mitochondrion of M.
  • Bacteria such as Veionella parvula, Neisseria subflava, and Neisseria bacteria such as Neisseria subflava are usually non-pathogenic indigenous bacteria.
  • the Streptococcus bacteria of the Mittis group are known to be involved in the elimination of pathogenic bacteria that cause periodontal diseases and the like.
  • the growth promoting effect of such oral resident bacteria, particularly Streptococcus bacteria of the Mittis group is excellent, and also has an antibacterial effect on pathogenic bacteria, so that the balance of oral resident bacteria is balanced. It is also possible to prevent it from collapsing and becoming pathogenic and maintaining a healthy state.
  • Patent Document 1 lysophosphatidylglycerol and / or phosphatidylglycerol has been confirmed to have antibacterial activity against pathogenic bacteria such as food poisoning bacteria, acne bacteria, and caries fungi, and its efficacy against other bacteria is not described and is unknown.
  • Patent Document 1 is different in at least the objective and target bacteria from the growth promoting action of the bacterium according to the present invention, which is the action opposite to that of antibacterial, and particularly the growth promoting action to oral resident bacteria.
  • composition for oral cavity containing a compound represented by the formula (1) or a salt thereof, wherein (A) / (B), which represents the ratio of component (A) to component (B), is 0.1 to 10 in terms of mass ratio.
  • (A) / (B) is 0.2 to 5 by mass ratio.
  • the compound represented by the above formula (1) is at least one lysophosphatidic acid selected from lysophosphatidic acid, lysophosphatidylcholine, lysophosphatidylserine, lysophosphatidylethanolamine, lysophosphatidylinositol and lysophosphatidylglycerin or a derivative thereof [ The composition for oral cavity according to [1] or [2].
  • the compound represented by the above formula (2) is at least one phosphatidic acid selected from phosphatidic acid, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine and phosphatidylinositol or a derivative thereof [1] to [3]
  • the composition for oral cavity of description [5] The composition for oral cavity according to any one of [1] to [4], containing 0.001 to 10% by mass of component (A) and 0.001 to 10% by mass of component (B).
  • the composition for oral cavity according to any one of [1] to [5] which is a preparation for oral cavity for increasing resident bacteria in the oral cavity.
  • a growth promoter for resident bacteria in the oral cavity comprising the compound represented by the above formula (1) or a salt thereof, and (B) the compound represented by the above formula (2) or a salt thereof.
  • B the compound represented by the above formula (2) or a salt thereof.
  • Oral resident bacteria are Streptococcus mitis, Streptococcus oralis and Streptococcus gordonii selected from one or more mitis group Streptococcus bacteria [7] or [8] .
  • a growth promoting agent for oral resident bacteria having an excellent effect of promoting the growth of oral resident bacteria and a composition for oral cavity containing the same. These are also effective in maintaining oral resident bacteria.
  • the growth promoting agent for oral resident bacteria of the present invention comprises (A) a compound represented by structural formula (1) or a salt thereof, and (B) a compound represented by structural formula (2) or a salt thereof.
  • the active ingredient comprises (A) a compound represented by structural formula (1) or a salt thereof, and (B) a compound represented by structural formula (2) or a salt thereof.
  • the component (A) is a compound represented by the following structural formula (1) or a salt thereof. These act as growth promoters for the resident bacteria in the oral cavity in combination with the component (B). It also acts as an antibacterial agent for pathogenic bacteria.
  • R 1 and R 2 are —OH and the other is —OCOR (where R is a saturated or unsaturated linear or branched hydrocarbon having 11 to 23 carbon atoms)
  • X 1 is —H, —C 2 H 4 N + (CH 3 ) 3 , —C 2 H 3 (N + H 3 ) COOH, —C 2 H 4 N + H 3 , —C 6 H 6 (OH) 5 or —C 2 H 3 (OH) CH 2 (OH).
  • R is a saturated or unsaturated linear or branched hydrocarbon group having 11 to 23 carbon atoms, preferably 15 to 21 carbon atoms.
  • the compound represented by the above formula (1) is preferably lysophosphatidic acid or a derivative thereof, such as lysophosphatidic acid (LPA, X 1 ; -H), lysophosphatidylcholine (LPC, X 1 ; -C 2).
  • LPA lysophosphatidic acid
  • LPC lysophosphatidylcholine
  • lysophosphatidic acid LPA
  • lysophosphatidylcholine LPC
  • lysophosphatidylethanolamine LPE
  • LPE lysophosphatidylserine
  • LPI lysophosphatidylinositol
  • LPE lysophosphatidylethanolamine
  • LPC lysophosphatidylcholine
  • LPE lysophosphatidylethanolamine
  • LPC particularly lysophosphatidylcholine
  • the above compound may be a salt, and examples of the salt include alkali metal salts such as sodium salts, ammonium salts and the like.
  • egg yolk lysolecithin LPL-1 egg yolk lecithin LPL-20W, egg yolk lecithin LPL-20S (manufactured by Kewpie Co., Ltd.), SLP-white lyso, SLP-LPC70, SLP-white lyso H, SLP- Commercial products such as LPC70H (manufactured by Sakai Oil Co., Ltd.) and LIPOID R LPC20 (manufactured by H. Holstein) can be used.
  • LPC70H manufactured by Sakai Oil Co., Ltd.
  • LIPOID R LPC20 manufactured by H. Holstein
  • the component (B) is a compound represented by the following structural formula (2) or a salt thereof. These act as growth promoters for oral resident bacteria when used in combination with the component (A). Moreover, it contributes also to moderate suppression of the antibacterial action by (A) component.
  • R 3 and R 4 may be the same or different from each other, and —OCOR 5 (R 5 is a saturated or unsaturated linear or branched chain having 11 to 23 carbon atoms)
  • X 2 is —H, —C 2 H 4 N + (CH 3 ) 3 , —C 2 H 3 (N + H 3 ) COOH, —C 2 H 4 N + H 3 , or —C 6 H 6 (OH) 5.
  • R 5 is a saturated or unsaturated linear or branched hydrocarbon group having 11 to 23 carbon atoms, preferably 15 to 21 carbon atoms.
  • the compound represented by the above formula (2) is preferably phosphatidic acid or a derivative thereof, such as phosphatidic acid (PA, X 2 ; -H), phosphatidylcholine (PC, X 2 ; -C 2 H 4). N + (CH 3) 3) , phosphatidylserine (PS, X 2; -C 2 H 3 (N + H 3) COOH), phosphatidylethanolamine (PE, X 2; -C 2 H 4 N + H 3) Phosphatidylinositol (PI, X 2 ; —C 6 H 6 (OH) 5 ) and the like. These may be used singly or in combination of two or more.
  • PA phosphatidic acid
  • X 2 ; -H phosphatidylcholine
  • PC X 2 ; -C 2 H 4
  • N + (CH 3) 3) phosphatidylserine
  • PS X 2; -C 2 H 3
  • phosphatidic acid (PA), phosphatidylcholine (PC), phosphatidylethanolamine (PE), and particularly phosphatidylcholine (PC) are preferable in terms of the effect of promoting the growth of oral resident bacteria.
  • the above compound may be a salt, and examples of the salt include alkali metal salts such as sodium salts, ammonium salts and the like.
  • egg yolk lecithin PL-100P egg yolk lecithin PL-30S (manufactured by Kewpie Corporation)
  • SLP-white SLP-PC70
  • SLP-white H SLP-PC70H
  • commercial products such as COATSOME NC-21 (manufactured by NOF Corporation) can be used.
  • (A) / (B) indicating the amount ratio of the component (A) to the component (B) is 0.1 to 10, preferably 0.2 to 5, and more preferably 0 as a mass ratio. .25-5. If it is less than 0.1, the effect of promoting the growth of oral resident bacteria is poor. If it exceeds 10, the antibacterial effect due to the component (A) is not suppressed, and antibacterial bacteria other than the pathogenic bacteria are also antibacterial, and the growth promoting effect of oral resident bacteria is poor.
  • the composition for oral cavity of the present invention is excellent in the growth promoting action of oral resident bacteria and also has an antibacterial action of oral pathogenic bacteria, the oral resident bacteria and / or the ratio thereof are increased (oral resident in the oral cavity).
  • Specific oral preparations include solids, liquids (including those in which some or all of the ingredients are dispersed or suspended without being solubilized; the same applies hereinafter), pastes, gels, etc.
  • tablets such as orally disintegrating tablets, chewable tablets, troches, candy, etc., granules such as granules, chewing gum, gummies, beverages, and toothpastes such as toothpaste, liquid toothpaste, liquid toothpaste, and toothpaste, It can be used in various dosage forms such as mouthwash, mouth spray, mouth freshener, and gel for coating.
  • the oral preparation may be a concentrated type, and may be prepared, for example, as a concentrated powder beverage that can be appropriately diluted with water.
  • the amount of component (A) is preferably 0.001 to 10% (mass%, the same applies hereinafter) of the entire composition, more preferably 0.01 to 5%, still more preferably 0.01 to 1. %.
  • the growth promoting effect of oral resident bacteria is sufficiently excellent, and when it is 10% or less, the growth promoting effect is sufficiently maintained.
  • the antibacterial action by the component (A) cannot be suppressed, and the growth promoting effect of oral resident bacteria may be inferior.
  • the amount of component (B) is not particularly limited, but is preferably 0.001 to 10%, more preferably 0.01 to 5%, still more preferably 0.01 to 1% of the entire composition. .
  • the growth promoting effect of oral resident bacteria is sufficiently excellent, and when it is 10% or less, the growth promoting effect is sufficiently maintained. If too much is added, the antibacterial action of the composition on pathogenic bacteria may be reduced, the bacterial flora balance in the oral cavity tends to be dominant, and the effect of maintaining a healthy state may be weakened.
  • composition for oral cavity of the present invention known components other than the above components (A) and (B) can be blended as necessary according to the purpose of use, dosage form and the like.
  • toothpastes such as toothpastes can be prepared by conventional methods by blending abrasives, thickeners, binders, surfactants, sweeteners, preservatives, colorants, fragrances, active ingredients, and the like. .
  • abrasive examples include silica-based abrasives such as precipitated silica, aluminosilicate, zirconosilicate, calcium phosphate-based abrasives, calcium carbonate and the like (the amount is usually 2 to 50%, particularly 10 to 40%). ).
  • thickener examples include sugar alcohols such as sorbit and xylit, glycerin, propylene glycol, and polyhydric alcohols such as polyethylene glycol having an average molecular weight of 160 to 4000 (average molecular weight described in Quasi-drug Raw Material Standard 2006) ( The blending amount is usually 5 to 50%).
  • binders include cellulose derivatives such as sodium carboxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, alginic acid or its derivatives such as sodium alginate, gums such as xanthan gum, organic binders such as carrageenan, polyvinyl alcohol, and sodium polyacrylate. And inorganic binders such as an agent, gelling silica, gelling aluminum silica, bee gum, and laponite (the blending amount is usually 0.1 to 10%).
  • the surfactant examples include an anionic surfactant and a nonionic surfactant.
  • the anionic surfactant include alkyl sulfates such as sodium lauryl sulfate and sodium myristyl sulfate, and acyl sarcosine salts.
  • Nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, sugar alcohol fatty acid esters, sorbitan fatty acid esters, glycerin fatty acid esters, polyglycerin fatty acid esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, etc. And polyoxyethylene fatty acid esters, polyoxyethylene higher alcohol ethers such as polyoxyethylene lauryl ether, and the like.
  • the blending amount of the surfactant is usually 0.01 to 10%, particularly 0.01 to 5%.
  • sweetening agent examples include sodium saccharin
  • preservative examples include paraoxybenzoic acid esters such as methyl paraoxybenzoate, benzoic acid such as sodium benzoate, and salts thereof.
  • colorant examples include blue No. 1, yellow No. 4, titanium dioxide and the like.
  • Perfumes include peppermint oil, spearmint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamom oil, coriander oil, mandarin oil, Lime oil, lavender oil, rosemary oil, laurel oil, camomil oil, caraway oil, marjoram oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie Natural fragrances such as oil, bran oil, Iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (front reservoir cut, rear reservoir cut, fractional distillation, liquid-liquid extraction, essence, powder Perfumes, etc.) and menthol, Rubon, Anethole, Cineol, Methyl salicylate, Synamic aldehyde, Eugenol, 3-l-Ment
  • Active ingredients include fluorine-containing compounds such as sodium fluoride and sodium monofluorophosphate, anti-inflammatory agents, enzymes such as dextranase, water-soluble phosphate compounds and copper compounds, vitamins, plant extracts, and calculus prevention Agents, anti-plaque agents and the like.
  • the active ingredient can be blended in an effective amount as long as the effects of the present invention are not hindered.
  • each bacterium was added to an evaluation sample or tryptic soy medium (TS medium, manufactured by Becton and Dickinson) to which distilled water (control) was added, in a 96-well plate. And aerobic culture at 37 ° C. for 12 hours. The amount of bacterial growth was measured by turbidity at a wavelength of 550 nm, and the degree of bacterial growth was evaluated. Before measuring the turbidity, the plate was shaken to stir the culture solution.
  • TS medium tryptic soy medium, manufactured by Becton and Dickinson
  • the growth degree of the bacteria was defined as the relative value Tr (Ts / Tc) of the turbidity (Ts) of the bacterial culture solution to which the evaluation sample was added relative to the turbidity (Tc) of the bacterial culture solution to which control (distilled water) was added. That is, if Tr is greater than 1.0, growth is promoted, and if it is less than 1.0, growth is inhibited (with antibacterial effect).
  • Ts / Tc Evaluation criteria Growth promotion effect of oral resident bacteria Tr (Ts / Tc) ⁇ : 1.5 or more ⁇ : 1.1 or more and less than 1.5 ⁇ : more than 1.0 and less than 1.1 ⁇ : 1.0 or less ⁇ : Less than 0.05 ⁇ : 0.05 or more and less than 0.2 ⁇ : 0.2 or more and less than 0.5 ⁇ : 0.5 or more
  • the bacteria used for the evaluation were the following bacterial species purchased from American Type Culture Collection (hereinafter abbreviated as ATCC). Oral resident bacteria: Streptococcus mitis ATCC 49456 (hereinafter abbreviated as S.mitis) Streptococcus oralis ATCC 9811 (hereinafter abbreviated as S. oralis) Streptococcus gordonii ATCC 10558 (hereinafter abbreviated as S. gordonii)
  • Periodontal pathogens Porphyromonas gingivalis ATCC 33277 (hereinafter abbreviated as P. gingivalis)
  • a compounding quantity is a pure part conversion value.
  • component (A) and the component (B) The following were used as the component (A) and the component (B).
  • Powdered beverage prepared by adding 100 mL of hot water or water
  • A -ii 0.5
  • B -ii 0.1
  • Powdered green tea 1.0
  • Total 1.6g (A) / (B) 1.4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Birds (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Tea And Coffee (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un promoteur de croissance de bactéries buccales communes contenant (A) un composé représenté par la formule structurale (1) ou un sel de celui-ci et (B) un composé représenté par la formule structurale (2) ou un sel de celui-ci, où le rapport (A)/ (B) est de préférence de 0,1 à 10 en poids ; et une composition à usage oral contenant le promoteur de croissance de bactéries buccales communes. (Dans la formule (1), un des R1 et R2 représente -OH et l'autre représente -OCOR (où R représente un groupe hydrocarbure en C11-23) ; et X1 représente -H, -C2H4N+(CH3)3, -C2H3(N+H3)COOH, -C2H4N+H3, -C6H6(OH)5 ou -C2H3(OH)CH2(OH)). (Dans la formule (2), R3 et R4 représentent indépendamment -OCOR5 (où R5 représente un groupe hydrocarbure en C11-23) ; et X2 représente -H, -C2H4N+(CH3)3, -C2H3(N+H3)COOH, -C2H4N+H3 ou -C6H6(OH)5).
PCT/JP2018/022002 2017-06-12 2018-06-08 Composition à usage oral et promoteur de croissance de bactéries buccales communes WO2018230459A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201880039297.9A CN110740721B (zh) 2017-06-12 2018-06-08 口腔用组合物和口腔内常驻菌的生长促进剂
KR1020197038567A KR102614880B1 (ko) 2017-06-12 2018-06-08 구강용 조성물 및 구강 내 상재균의 생육 촉진제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017114841A JP6953811B2 (ja) 2017-06-12 2017-06-12 口腔用組成物及び口腔内常在菌の生育促進剤
JP2017-114841 2017-06-12

Publications (1)

Publication Number Publication Date
WO2018230459A1 true WO2018230459A1 (fr) 2018-12-20

Family

ID=64660023

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/022002 WO2018230459A1 (fr) 2017-06-12 2018-06-08 Composition à usage oral et promoteur de croissance de bactéries buccales communes

Country Status (4)

Country Link
JP (1) JP6953811B2 (fr)
KR (1) KR102614880B1 (fr)
CN (1) CN110740721B (fr)
WO (1) WO2018230459A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7215026B2 (ja) * 2018-09-13 2023-01-31 ライオン株式会社 口腔用組成物
JP7310149B2 (ja) * 2019-01-22 2023-07-19 ライオン株式会社 口腔用組成物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03118305A (ja) * 1989-09-29 1991-05-20 Yakult Honsha Co Ltd 抗菌剤
JPH05239A (ja) * 1991-06-21 1993-01-08 Taiyo Kagaku Co Ltd リポソーム
JPH07149619A (ja) * 1993-11-30 1995-06-13 Earth Chem Corp Ltd 口腔用組成物
JP2005525335A (ja) * 2002-02-12 2005-08-25 ウンザー ディ ピストレージ エルヴィラ エ チ． エッセ．ア．エッセ． Ｎ−アシル−ホスファチジル−エタノールアミン類及び／又はｎ−アシル−エタノールアミン類とホスファチジン酸類又はリゾホスファチジン酸類との混合物
JP2014088333A (ja) * 2012-10-29 2014-05-15 Univ Of Tokushima 口腔咽頭用組成物
JP2016501709A (ja) * 2012-10-24 2016-01-21 カーギル インコーポレイテッド リン脂質含有乳化剤組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02273536A (ja) * 1989-04-13 1990-11-08 Yakult Honsha Co Ltd 界面活性剤およびその製造法
JP2717509B2 (ja) 1993-07-01 1998-02-18 花王株式会社 苦味低減化剤及び苦味低減化法
US5407921A (en) * 1993-07-01 1995-04-18 Kao Corporation Method for suppressing bitter taste
MX2017005028A (es) * 2014-10-20 2017-12-04 Int Flavors & Fragrances Inc Nanoemulsiones de aroma y metodos de preparacion de las mismas.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03118305A (ja) * 1989-09-29 1991-05-20 Yakult Honsha Co Ltd 抗菌剤
JPH05239A (ja) * 1991-06-21 1993-01-08 Taiyo Kagaku Co Ltd リポソーム
JPH07149619A (ja) * 1993-11-30 1995-06-13 Earth Chem Corp Ltd 口腔用組成物
JP2005525335A (ja) * 2002-02-12 2005-08-25 ウンザー ディ ピストレージ エルヴィラ エ チ． エッセ．ア．エッセ． Ｎ−アシル−ホスファチジル−エタノールアミン類及び／又はｎ−アシル−エタノールアミン類とホスファチジン酸類又はリゾホスファチジン酸類との混合物
JP2016501709A (ja) * 2012-10-24 2016-01-21 カーギル インコーポレイテッド リン脂質含有乳化剤組成物
JP2014088333A (ja) * 2012-10-29 2014-05-15 Univ Of Tokushima 口腔咽頭用組成物

Also Published As

Publication number Publication date
KR102614880B1 (ko) 2023-12-18
CN110740721A (zh) 2020-01-31
JP2019001720A (ja) 2019-01-10
KR20200014357A (ko) 2020-02-10
JP6953811B2 (ja) 2021-10-27
CN110740721B (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
JP6318487B2 (ja) 口腔用組成物
JP2007332143A (ja) 口臭を抑える抗菌作用を持った化合物
WO2015008823A1 (fr) Agent d'élimination de biofilm de la cavité buccale et composition pour cavité buccale
JP6834978B2 (ja) 歯磨剤組成物及び口腔バイオフィルム除去剤
JP2011098918A (ja) 歯磨剤組成物
JP5493731B2 (ja) 歯磨剤組成物
JPWO2016093279A1 (ja) 口腔用組成物
JP6740901B2 (ja) 口腔用組成物及び口腔用組成物におけるカチオン性殺菌剤の異味抑制方法
JP6795839B2 (ja) バイオフィルム抑制剤
WO2018230459A1 (fr) Composition à usage oral et promoteur de croissance de bactéries buccales communes
JP2007161598A (ja) 歯磨剤組成物
JP2020011951A (ja) 口腔用組成物
JP2005047855A (ja) 口腔バイオフィルム抑制剤及び口腔用組成物
JP2011046654A (ja) 歯磨剤組成物
JP7423925B2 (ja) 口腔内常在菌の生育促進剤及び口腔用組成物
WO2018066341A1 (fr) Composition pour cavité buccale, et procédé d'inhibition de variation de couleur de préparation et de séparation de liquide associés
JP6547324B2 (ja) 液体口腔用組成物
JP2017214296A (ja) 口腔用組成物
JP7445910B2 (ja) 口腔常在菌調整剤を含む口腔用組成物、口腔ケア製品及び食品
WO2019208699A1 (fr) Agent pour améliorer la flore bactérienne dans la cavité buccale, et composition buccale
JP4158036B2 (ja) 歯磨剤組成物及びその製造方法
JP2017007993A (ja) 口腔用組成物及び口腔バイオフィルム殺菌剤
JP6249588B2 (ja) 口腔用組成物
JP7215026B2 (ja) 口腔用組成物
JP2017007991A (ja) 口腔用組成物及び該組成物におけるヒノキチオールの殺菌力向上方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18818537

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20197038567

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 18818537

Country of ref document: EP

Kind code of ref document: A1